Belka, M.; Gostyńska-Stawna, A.; Sommerfeld-Klatta, K.; Stawny, M.; Krajka-Kuźniak, V.
Nobiletin Attenuates Inflammation and Modulates Lipid Metabolism in an In Vitro Model of Intestinal Failure-Associated Liver Disease. Pharmaceutics 2026, 18, 87.
https://doi.org/10.3390/pharmaceutics18010087
AMA Style
Belka M, Gostyńska-Stawna A, Sommerfeld-Klatta K, Stawny M, Krajka-Kuźniak V.
Nobiletin Attenuates Inflammation and Modulates Lipid Metabolism in an In Vitro Model of Intestinal Failure-Associated Liver Disease. Pharmaceutics. 2026; 18(1):87.
https://doi.org/10.3390/pharmaceutics18010087
Chicago/Turabian Style
Belka, Marta, Aleksandra Gostyńska-Stawna, Karina Sommerfeld-Klatta, Maciej Stawny, and Violetta Krajka-Kuźniak.
2026. "Nobiletin Attenuates Inflammation and Modulates Lipid Metabolism in an In Vitro Model of Intestinal Failure-Associated Liver Disease" Pharmaceutics 18, no. 1: 87.
https://doi.org/10.3390/pharmaceutics18010087
APA Style
Belka, M., Gostyńska-Stawna, A., Sommerfeld-Klatta, K., Stawny, M., & Krajka-Kuźniak, V.
(2026). Nobiletin Attenuates Inflammation and Modulates Lipid Metabolism in an In Vitro Model of Intestinal Failure-Associated Liver Disease. Pharmaceutics, 18(1), 87.
https://doi.org/10.3390/pharmaceutics18010087